Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ritter Pharmaceuticals (RTTR) Reports Q3 Loss of $0.40/Share
November 17, 2015 8:39 AM ESTRitter Pharmaceuticals (NASDAQ: RTTR) reported Q3 EPS of ($0.40), versus ($0.92) reported last year.
"Following our successful initial public offering in June, we have been working diligently to execute our business strategy and prepare for our upcoming Phase 2b/3 clinical trial of RP-G28, the potentially first FDA-approved therapy for lactose intolerance, in early 2016. We are pleased to say that we have made significant progress with these efforts, efficiently utilizing our capital resources to... More
